Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy
Oncologic treatment has recently undergone substantial therapeutic paradigm shifts, from classical tumor-specific and biomarker-agnostic approaches to more molecular, biomarker-specific, and tumor-agnostic. Tumor-type (histology) agnostic drugs work across cancer types and present a novel shift in...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2024-04-01
|
| coleção: | Biomolecules & Biomedicine |
| Assuntos: | |
| Acesso em linha: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/10641 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|